1. Pink Sheet

More Remdesivir Data, More Questions Linger

 
• By Derrick Gingery

The latest data on the NIAID’s ACTT-1 study offers more help for clinicians trying to determine which coronavirus patients should receive remdesivir, but selection criteria – and supply – remain uncertain.

Coronavirus
Clinicians have some clues about the best patients for remdesivir, but say more information still is needed after studies were published. • Source: Shutterstock

Additional positive clinical data about Gilead Sciences Inc.’s remdesivir in coronavirus disease was welcome news for clinicians, but may only answer a few of the many questions about the optimal use of the antiviral.

The New England Journal of Medicine on 22 May published a preliminary report with remdesivir data from the placebo-controlled ACTT-1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D